amyotrophic lateral sclerosis amyotrophic lateral sclerosis
Conditions
Sponsors
Tansy Aaron
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males or females aged between 18 and 80 years with a body mass index between 18 and 35 kg/m2 at the time of the initial Screening Visit 2. Onset of the first symptom leading to the diagnosis of ALS is within 24 months at the time of the initial Screening Visit 3. Revised El Escorial criteria of either: (i) Clinically definite ALS (ii) Clinically probable ALS 4. A total ALSFRS-R score of at least 34 at the start of the Screening Period
Exclusion criteria
Exclusion criteria: 1.History of allergies or adverse reactions to any of the excipients in the study drug formulation 2. Liver failure (except in Gilbert syndrome, defined as AST and/or ALT 3 times the upper limit of normal [ULN] or liver function test [LFT] with bilirubin 1.5 times the ULN)) 3. Moderate to severe renal failure (defined as estimated glomerular filtration rate [eGFR] less than 60 mL/min) 4. Currently participating in a clinical trial of another investigational drug, or have participated 30 days prior to the start of the screening period or 5 half-lives from the most recent dose of the investigational drug, whichever is longer. 5. History of alcohol or drug abuse within 6 months prior to the start of the screening period 6. Patient has received combination therapy with edaravone and sodium phenylbutyrate/taurursodiol within 30 days prior to the start of the screening period. 7. History of breast cancer (regardless of remission status) or history of breast cancer in a first-degree relative
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) in the Intent-To-Treat 1 (ITT1) Analysis Set after 24 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change from baseline in ALSFRS-R in the Intent-to-Treat 2(ITT2) Analysis Set after 24 weeks of treatment 2. Safety and tolerability of PTC857 as measured by the severity and number of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events(TESAEs), and change in clinical laboratory tests, physical examination, vital signs, Columbia-Suicide Severity Rating Scale(C-SSRS), and 12-lead electrocardiograms (ECGs) during the Treatment Period 3. Change from baseline in respiratory function as assessed by pulmonary function tests (PFTs) after 24 weeks of treatment 4. Change from baseline in motor/limb and bulbar function as assessed by the Modified Norris Scale after 24 weeks of treatment 5. Change from baseline in neuropsychological function as assessed by the ALS Cognitive Behavioral Screen (ALS CBS) after 24 weeks of treatment 6. Survival as assessed by rate of and length of time to needing respiratory support/intubation and/or death 7. Survival and functional change as assessed by the Combined Assessment of Function and Survival (CAFS) after 24 weeks of treatment 8. Quality of life as assessed by Amyotrophic Lateral Sclerosis Assessment Questionnaire(ALSAQ-40)after 24 weeks of treatment 9. Plasma PK and cerebrospinal fluid (CSF) exposure of PTC857 | — |
Countries
Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Spain, Sweden, US
Contacts
Public ContactRobert Phillips
Worldwide Clinical Trials Japan K.K.
Outcome results
None listed